Clinical Trial Update: Gemcitabine/Oxaliplatin (GEMOX) vs Carboplatin/Paclitaxel (CP) in Non-Small Cell Lung Cancer (NSCLC) [Phase 3]

View source ↗

Summary

Phase 3 randomized study comparing GEMOX (gemcitabine/oxaliplatin) to CP (carboplatin/paclitaxel) in non-small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Eloxatin (oxaliplatin)
• Gemzar (gemcitabine)
• Paraplatin (Carboplatin)
• Taxol (paclitaxel)

Snippet

Sponsor: Sanofi | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 3 | Status: COMPLETED